Pharmacogenomics of Sorafenib in Hepatocellular Carcinoma (HCC): A LncRNA-Expression Guided Approach Using UCA1 and MALAT1 for Personalizing Therapy in a 154-Patient Cohort.

The fact that these externally derived cut-offs achieved highly significant survival stratification (log-rank p ≤ 0.003) and independent multivariable significance ( p ≤ 0.014) in our larger therapeutic cohort constitutes cross-validation, demonstrating these thresholds capture genuine biological risk rather than dataset-specific statistical artifacts.

also in 132,142 other papers